Treating and Managing Patients with Cardiovascular Disease

  HCVinHIV_Disease_Banner_v1

 

About the Program:

Program Overview:

As many as 7 million people worldwide are infected with both HIV and HCV. Because of the potential consequences of HCV infection, clinicians who care for HCV/HIV co-infected patients face many complex treatment issues, including when to start treatment, which treatments to use, how long to treat patients, and which treatments can be safely combined in this population. In addition, they must remain abreast of rapidly changing information on the treatment of HCV/HIV co-infected patients. This program, "Managing HCV/HIV Co-Infection: What Clinicians Need to Know," is a series of six internet symposia, each covering a specific topic in the treatment of HCV/HIV co-infected patients. Each one-hour symposium will feature an interview of an expert in the field of HCV treatment, who will review and discuss the most essential information and data HIV clinicians need to know.

The sixth internet symposium is being brought to you from Baltimore, Maryland and will cover, "Treating and Managing Patients with Cardiovascular Disease." This program will feature an interview with Wendy Post, MD, from Johns Hopkins University by Mark Sulkowski, MD, from Johns Hopkins University. Dr. Post is a leading expert on Cardiovascular Disease.

Back to Top

Target Audience:

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV and HCV infection.

Back to Top

Learning Objectives:

After completing this activity, the participant should be better able to:

  • Appropriately screen patients for HCV to identify HCV/HIV co-infected patients in their practice
  • Develop effective strategies for treating HCV in HIV-positive patients
  • Apply the most recent information to the treatment of HCV/HIV co-infected patients to avoid drug-drug interactions, minimize adverse effects, and achieve successful outcomes
  • Discuss research on HCV drugs in development to apply this information to ongoing treatment decisions
Back to Top

Faculty:

Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Wendy Post, MD
Professor of Medicine
Johns Hopkins University School of Medicine
Professor of Epidemiology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Back to Top

Physician Continuing Medical Education:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this live program for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Back to Top

European Continuous Medical Education Credit:

AMA PRA Category 1 Credits claimed by physicians attending live events certified and organized in the United States for AMA PRA Category 1 Credits™ can be claimed through the agreement on mutual recognition of credits between UEMS and AMA, considered as being equal to the European Continuous Medical Education Credits (ECMEC®) granted by the UEMS. One AMA PRA Category 1 Credit is equivalent to one (1) hour of European EACCME Credit (ECMEC®), therefore up to 1.0 ECMEC® Credits are available.

Back to Top

Disclosure of Conflicts of Interest:

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Back to Top
 

PIM_small

VE logo 300px
 

  This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs

*Greenwich Mean Time



Prepare to print

Share this page:

Get link code to this page                     


Back to Top